A rare gastric neuroendocrine carcinoma coexisting with Brunner's gland adenoma: A case report

Wei,Jian‑Ming; Zhang,Zi‑Zhen; Shen,Yan‑Ying; Shen,Dan‑Ping; Ni,Xing‑Zhi

doi:10.3892/ol.2015.3465

A rare gastric neuroendocrine carcinoma coexisting with Brunner's gland adenoma: A case report

Authors:
- Jian‑Ming Wei
- Zi‑Zhen Zhang
- Yan‑Ying Shen
- Dan‑Ping Shen
- Xing‑Zhi Ni
View Affiliations

Affiliations: Department of General Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, P.R. China
Published online on: July 8, 2015 https://doi.org/10.3892/ol.2015.3465
Pages: 1251-1254
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric neuroendocrine carcinoma (G-NEC) is a rare neoplasm known for its aggressive behavior and poor prognosis. Brunner's gland adenoma (BGA) is a rare benign proliferative lesion that develops most commonly in the duodenum. To the best of our knowledge, no cases of G‑NEC coexisting with BGA have previously been reported. The present study therefore reports the first case of G‑NEC combined with BGA. A 67‑year‑old female presented with upper abdominal discomfort. No distant metastases were detected upon pre‑operative abdominal computed tomography imaging. The patient underwent a radical distal gastrectomy, D2 lymphadenectomy and Billroth I gastroenterostomy. The resected masses were histologically confirmed to be G‑NEC and BGA, respectively. The patient did not receive neoadjuvant or adjuvant chemotherapy or radiotherapy, and remains alive with no evidence of metastasis or recurrence at four years post-surgery.

View Figures

View References

1	Nishikura K, Watanabe H, Iwafuchi M, Fujiwara T, Kojima K and Ajioka Y: Carcinogenesis of gastric endocrine cell carcinoma: analysis of histopathology and p53 gene alteration. Gastric Cancer. 6:203–209. 2003. View Article : Google Scholar : PubMed/NCBI
2	Gao YP, Zhu JS and Zheng WJ: Brunner's gland adenoma of duodenum: a case report and literature review. World J Gastroenterol. 10:2616–2617. 2004.PubMed/NCBI
3	Coskun A and Erkan N: Giant Brunner's gland adenoma as an unusual cause of anaemia: Report of a case. Radiol Oncol. 45:129–131. 2011. View Article : Google Scholar : PubMed/NCBI
4	Stewart ZA, Hruban RH, Fishman EF and Wolfgang CL: Surgical management of giant Brunner's gland hamartoma: case report and literature review. World J Surg Oncol. 7:682009. View Article : Google Scholar : PubMed/NCBI
5	Masaru Koizumi, Sata N, Yoshizawa K, Kurihara K and Yasuda Y: Carcinoma arising from Brunner's gland in the duodenum after 17 years of observation - a case report and literature review. Case Rep Gastroenterol. 1:103–109. 2007. View Article : Google Scholar : PubMed/NCBI
6	Rindi G, Klöppel G, Alhman H, et al: all other Frascati Consensus Conference participants; European Neuroendocrine Tumor Society (ENETS): TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449:395–401. 2006. View Article : Google Scholar : PubMed/NCBI
7	Toumpanakis CG and Caplin ME: Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol. 103:729–732. 2008. View Article : Google Scholar : PubMed/NCBI
8	Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Klöppel G, et al: Nomenclature and classification of neuroendocrine neoplasms of the digestive systemWHO Classification of Tumors of the Digestive System. Bosman FT, Carneiro F, Hruban RH and Theise ND: 4th. IARC Press; Lyon, France: pp. 13–14. 2010
9	Uchiyama C, Tamura S, Nakatsuka S, et al: Immunohistochemical consistency between primary tumors and lymph node metastases of gastric neuroendocrine carcinoma. World J Surg Oncol. 10:1152012. View Article : Google Scholar : PubMed/NCBI
10	Massironi S, Sciola V, Peracchi M, et al: Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 14:5377–5384. 2008. View Article : Google Scholar : PubMed/NCBI
11	Solcia E, Klöppel G and Sobin LH: WHO International Histological Classification of Tumors: Histological Typing of Endocrine Tumors. 2nd. Springer-Verlag; Berlin: pp. 56–70. 2000
12	Fendrich V and Bartsch DK: Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg. 396:299–311. 2011. View Article : Google Scholar : PubMed/NCBI
13	Susini C and Buscail L: Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 17:1733–1742. 2006. View Article : Google Scholar : PubMed/NCBI
14	Mejias M, Garcia-Pras E, Tiani C, et al: The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats. J Cell Mol Med. 12:1690–1699. 2008. View Article : Google Scholar : PubMed/NCBI
15	Panzuto F, Di Fonzo M, Iannicelli E, et al: Long term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. 17:461–466. 2006. View Article : Google Scholar : PubMed/NCBI
16	Matsumoto T, Iida M, Matsui T, et al: A large Brunner's gland adenoma removed by endoscopic polypectomy. Endoscopy. 22:192–193. 1990. View Article : Google Scholar : PubMed/NCBI
17	Rocco A, Borriello P, Compare D, De Colibus P, Pica L, Iacono A and Nardone G: Large Brunner's gland adenoma: case report and literature review. World J Gastroenterol. 12:1966–1968. 2006.PubMed/NCBI
18	Rufenacht H, Kasper M, Heitz PU, et al: ‘Brunneroma’: hamartoma or tumor? Pathol Res Pract. 181:107–111. 1986. View Article : Google Scholar : PubMed/NCBI
19	Levine JA, Burgart LJ, Batts KP and Wang KK: Brunner's gland hamartomas: clinical presentation and pathological features of 27 cases. Am J Gastroenterol. 90:290–294. 1995.PubMed/NCBI